KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Friday said its
Keytruda in combination with fluoropyrimidine- and
platinum-containing-chemotherapy has been approved by Health Canada for the
treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma in
adults.

This approval is based on results from the Phase 3 KEYNOTE-859 trial, in which
treatment with Keytruda plus chemotherapy showed statistically significant
improvement in overall survival (OS), progression-free survival (PFS) and
objective response rate (ORR) compared to placebo in combination with
chemotherapy in patients with gastric cancers.

Keytruda was first approved in 2014 by the US FDA to treat advanced or
unresectable melanoma. It is currently approved for several indications
including advanced renal cell carcinoma, bladder cancer, non-small cell lung
carcinoma, cervical cancer, among others.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX